Scholar Rock: Director Buys $8M as Short Interest Hits Year High

SRRK reports Q3 results on November 10 with a striking split in its data: a director spent roughly $8 million buying shares in the open market two weeks ago, while short interest climbed to its highest level in at least a year.

That insider conviction is the sharpest fact in the setup. Director Srinivas Akkaraju purchased approximately 289,000 shares across October 23 and 26, paying around $41.30 to $41.59 per share, with no 10b5-1 plan attached. The purchases were entirely discretionary. That cluster of trades came in below the current price of $51.55, meaning Akkaraju is already sitting on a gain of roughly 24% in two weeks. Net insider buying over the past 90 days totals approximately $12 million across all filings.

Akkaraju also carries activist status on SRRK's 13D register, with a Schedule 13D/A on file representing 7.2% of the class as last disclosed. The 13D designation is itself notable: it signals intent beyond passive ownership. As always with 13D/G filings, the stake is as of the last disclosure date and positions can change without a further filing if a holder drops below 5%.

Short interest, meanwhile, has moved in the opposite direction to the insider. At 23.4% of the free float, it has risen 16.7% over the past month and reached its highest reading in the data series. Despite that, the borrow market is not tight. Availability is 155%, meaning roughly 1.5 shares remain available to borrow for every share already lent out, and the cost to borrow has fallen 30% over the past week to just 0.45%. That combination, high short interest but easy borrow conditions, reflects a disagreement between investors rather than a supply squeeze. Options positioning does not suggest unusual stress either, with the put/call ratio at 0.69, slightly below its 20-day average of 0.75.

The bull case rests on ISEMBYLD's FDA approval covering roughly 6,600 treated SMA patients with no restrictions on subtype or prior therapy, pricing implying around $310,000 in annual net revenue per patient, and peak global sales projections around $2.4 billion. Bears focus on reimbursement risk: insurers may treat ISEMBYLD differently from SMN-preserving therapies given it does not protect motor neurons, and the clinical effect size, a 2.2-point HFMSE improvement in SAPPHIRE, has drawn some KOL caution. A wave of analyst target increases followed positive Phase 3 data in mid-September, with Truist, JPMorgan, Evercore, and others all raising targets. Those moves are now around seven weeks old. Barclays moved to Equal-Weight on September 15, the lone downgrade in that cluster. The mean price target of roughly $70 implies about 36% upside from Friday's close, though that consensus was struck before the recent 20% weekly move.

SRRK gained 20.1% over the past week, against a median of roughly 7% for its closest peers. RYTM and PRAX each rose around 21 to 22% on the week, suggesting some sector-wide lift. CTMX fell 11%, the outlier in the group.

ORTEX also forecasts a 52% chance of a share count increase in the CRSP US Small index at the December 2026 Quarterly Review, with an estimated $78 million in associated tracker buying over approximately one day of normal volume. That is a forecast, not a confirmed change; the rank date is December 4.

The print will test whether the commercial launch trajectory for ISEMBYLD is running ahead of or behind what the recent run-up in the stock and the director's open-market buying together imply.